According to a recent LinkedIn post from Insilico Medicine, the company’s ongoing ScienceAIBench series has released benchmarking results focused on identifying clinical-stage targets for three cardiovascular indications: heart failure, ischemia, and pulmonary arterial hypertension. The post outlines model performance using Mean Average Precision at TopK, comparing leading AI systems including GPT 5, Opus 4.1, Gemini 2.5 Pro, DeepSeek R1, and Grok 4.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The benchmarking suggests that GPT 5 led in heart failure target retrieval with a score of 0.715, while Opus 4.1 slightly outperformed GPT 5 in ischemia, and DeepSeek R1 was strongest in pulmonary arterial hypertension. The post also notes that overall performance differences among top models are relatively narrow, particularly in heart failure, implying a broadly solid baseline capability in AI-driven cardiac pharmacology.
For investors, the series underscores Insilico Medicine’s emphasis on rigorous, quantitative AI benchmarking in complex therapeutic areas, which may support the credibility of its platform in drug discovery partnerships and business development discussions. While the post focuses on comparative technical performance rather than commercial milestones, continued visibility of these benchmarks could enhance the company’s positioning in AI-enabled biotechnology and attract interest from pharmaceutical collaborators.